Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients
Abstract Rare cancers present significant challenges in diagnosis, treatment, and research, accounting for up to 25% of global cancer cases. Due to their rarity and atypical presentations, they are often misdiagnosed, resulting in late-stage detection and poor outcomes. Here, we describe a patient c...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-024-00768-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586100158234624 |
|---|---|
| author | Sarah Haebe Gesa Schuebbe Philipp Jurmeister Michael von Bergwelt-Baildon C. Benedikt Westphalen Ulrich M. Lauer Wolfgang G. Kunz Marion Subklewe Oliver Weigert |
| author_facet | Sarah Haebe Gesa Schuebbe Philipp Jurmeister Michael von Bergwelt-Baildon C. Benedikt Westphalen Ulrich M. Lauer Wolfgang G. Kunz Marion Subklewe Oliver Weigert |
| author_sort | Sarah Haebe |
| collection | DOAJ |
| description | Abstract Rare cancers present significant challenges in diagnosis, treatment, and research, accounting for up to 25% of global cancer cases. Due to their rarity and atypical presentations, they are often misdiagnosed, resulting in late-stage detection and poor outcomes. Here, we describe a patient case with advanced metastatic nasopharynx NUT carcinoma, one of the rarest and most aggressive cancers. We conducted a comprehensive analysis of this patient’s tumor, including Tumor Mutation Burden, Microsatellite Instability, and genetic profiling to explore further putative druggable targets. The tumor exhibited high PD-L1 expression and showed a notable response to immune checkpoint inhibitors when combined with platinum-based radio-chemotherapy. Our findings indicate that checkpoint inhibitors could play a critical role in treating NUT carcinoma, offering new therapeutic avenues and hope for patients with this challenging diagnosis. Whether PD-L1 expression may be a useful predictor of immune checkpoint inhibitor efficacy warrants further research. |
| format | Article |
| id | doaj-art-f983ad34aec84644a35568bcf6f69bae |
| institution | Kabale University |
| issn | 2397-768X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj-art-f983ad34aec84644a35568bcf6f69bae2025-01-26T12:12:53ZengNature Portfolionpj Precision Oncology2397-768X2025-01-01911610.1038/s41698-024-00768-7Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patientsSarah Haebe0Gesa Schuebbe1Philipp Jurmeister2Michael von Bergwelt-Baildon3C. Benedikt Westphalen4Ulrich M. Lauer5Wolfgang G. Kunz6Marion Subklewe7Oliver Weigert8Department of Medicine III, LMU University HospitalDepartment of Medicine III, LMU University HospitalDepartment of Pathology, LMU University HospitalDepartment of Medicine III, LMU University HospitalDepartment of Medicine III, LMU University HospitalDepartment of Medicine VIII, University Hospital TübingenDepartment of Radiology, LMU University HospitalDepartment of Medicine III, LMU University HospitalDepartment of Medicine III, LMU University HospitalAbstract Rare cancers present significant challenges in diagnosis, treatment, and research, accounting for up to 25% of global cancer cases. Due to their rarity and atypical presentations, they are often misdiagnosed, resulting in late-stage detection and poor outcomes. Here, we describe a patient case with advanced metastatic nasopharynx NUT carcinoma, one of the rarest and most aggressive cancers. We conducted a comprehensive analysis of this patient’s tumor, including Tumor Mutation Burden, Microsatellite Instability, and genetic profiling to explore further putative druggable targets. The tumor exhibited high PD-L1 expression and showed a notable response to immune checkpoint inhibitors when combined with platinum-based radio-chemotherapy. Our findings indicate that checkpoint inhibitors could play a critical role in treating NUT carcinoma, offering new therapeutic avenues and hope for patients with this challenging diagnosis. Whether PD-L1 expression may be a useful predictor of immune checkpoint inhibitor efficacy warrants further research.https://doi.org/10.1038/s41698-024-00768-7 |
| spellingShingle | Sarah Haebe Gesa Schuebbe Philipp Jurmeister Michael von Bergwelt-Baildon C. Benedikt Westphalen Ulrich M. Lauer Wolfgang G. Kunz Marion Subklewe Oliver Weigert Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients npj Precision Oncology |
| title | Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients |
| title_full | Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients |
| title_fullStr | Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients |
| title_full_unstemmed | Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients |
| title_short | Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients |
| title_sort | adding checkpoint inhibitors to first line chemotherapy for nut carcinoma patients |
| url | https://doi.org/10.1038/s41698-024-00768-7 |
| work_keys_str_mv | AT sarahhaebe addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT gesaschuebbe addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT philippjurmeister addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT michaelvonbergweltbaildon addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT cbenediktwestphalen addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT ulrichmlauer addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT wolfganggkunz addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT marionsubklewe addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients AT oliverweigert addingcheckpointinhibitorstofirstlinechemotherapyfornutcarcinomapatients |